Topic Highlight
Copyright ©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 21, 2013; 19(47): 8887-8894
Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.8887
Table 1 Risk factors and prediction scores for hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma
Risk factorsHBV-related HCCHCV-related HCC
Increased age[11-15][16]
Male gender[11,12,15][16]
Increased serum HBV DNA levels[11,12,14,15]
Presence of cirrhosis[12-14]
Increased serum ALT concentration[11,15]
HBeAg positivity[11,15]
Presence of core promoter mutations[12]
Presence of virological remission after 24 mo[13]
Presence of hypoalbuminemia[13]
Decreased serum albumin[14]
Increased serum bilirubin[14]
HBV genotype C[15]
Presence of HBsAg[15]
Family history of HCC[15]
Presence of portal hypertension[16]
Presence of hepatic inflammation[16]
Increased iron storage levels[16]
Presence of sustained virological response[17]
Presence of complete viral suppression[17]
Table 2 Antiviral interventions for prevention of hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma
Antiviral interventionsHBV-related HCCHCV-related HCC
IFN: IFN-α+/-[28,29][46]
Pegylated IFN[47]
NAs: Lamivudine[36]
Entecavir[37,38]
Ribavirin[47]
Vaccination[21,22]
Screening of blood product[27][27]
Table 3 Chemopreventive agents for hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma
Chemopreventive agentsHBV-related HCCHCV-related HCC
Statins[42]
Antidiabetic medications[42][42]
Aspirin[41,53][53]
Propranolol[51]
FASN[52]
Dietory agents: Coffee[54][54]
Vitamin E[54][54]
Vitamin D[50]
Fish oil (n-3 PUFA)[55-57][55-57]
Phytochemicals: Resveratrol[43]
EGb[44]